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Because of its physical properties, apolioprotein B (apo B) has remained poorly characterized. In an at- 
tempt o elucidate apo B structure, the Fab fragments of 3 different monoclonal nti-human apo B anti- 
bodies were tested in a quantitative assay for their binding to human low density lipoprotein (LDL). In 
each case the assay gave a linear Scatchard plot with a maximum of 1 Fab fragment bound to a single 
LDL particle. This result favors an LDL model containing a single large Mr apo B protein, which is not 
composed of multiple, identical, small Mr subunits. 
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1. INTRODUCTION 
Apolipoprotein (apo) B is the major protein 
found in low density lipoprotein (LDL), the princi- 
pal carrier of plasma cholesterol in humans. In its 
delipidated form, apo B is extremely insoluble in 
aqueous buffers. In addition, apo B is susceptible 
to proteolysis [1,2], oxidative cleavage [3] and 
when delipidated, it tends to aggregate even in the 
presence of sodium dodecyl sulphate [3,4]. These 
properties have presented enormous technical 
problems in attempts to determine the structure of 
apo B. As a consequence, reported Mr-values 
range from 8 x 103 [5] to 5.5 × 105 [6]. We report 
here a stoichiometric titration of antigenic determi- 
nants on LDL particles using the Fab fragments of 
3 monoclonal antibodies against apo B. The results 
indicate that apo B is a large Mr protein and is not 
assembled from identical small subunits. 
2. MATERIALS AND METHODS 
2.1. Preparation of LDL 
Blood from normal subjects was collected into 
EDTA and the red blood cells were removed by 
centrifugation. Lipoprotein subfractions were pre- 
pared in a Beckman L5-65 ultracentrifuge with a 
50.2 Ti rotor (Beckman Instruments, Spinco Div., 
Palo Alto CA). LDL were isolated by successive 
ultracentrifugations at 4°C [7] between densities of 
1.030-1.050g/ml, dialysed exhaustively against 
phosphate-buffered saline (PBS) containing 1mM 
EDTA and 0.02% sodium azide, sterilized by ultra- 
filtration and stored at 4°C. In certain experi- 
ments, 150 mg phenylmethylsulphonylfluoride 
(PMSF) in 0.5 ml dimethylsulphoxide was added 
to 100 ml freshly drawn blood before preparation 
of the LDL fraction [2]. 
2.2. Monoclonal antibodies against LDL 
Hybridomas which secrete monoclonal anti- 
human LDL were the product of a cell fusion be- 
tween cells of the plasmacytoma cell line SP2-0 [8] 
and isolated spleen cells from BALB/c mice pre- 
viously immunized with human LDL. Details of 
the cell fusion and characterization f the mono- 
clonal antibodies are described in [9]. 
2.3. Preparation of Fab fragments 
The IgG subclass containing the anti-apo B 
monoclonal antibody was isolated from the ascitic 
fluid of hybridoma-bearing mice by elution from 
protein A-Sepharose 4B (Pharmacia Inc., Upp- 
sala) with a step-wise pH gradient [10]. Papain di- 
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gestion of the isolated immunoglobulin was done 
as in [11]. Undigested IgG and Fc fragments were 
removed by passage on protein A-Sepharose 4B, 
The anti-LDL Fab fragments in the non-retained 
fraction were purified by adsorption onto and elu- 
tion from LDL-Sepharose 4B [12] using 0.05 M 
citric acid containing 1M NaC1 (pH 2.6) as the 
eluting agent. The pure Fab fragments were imme- 
diately dialysed against PBS. Fab fragments 
(50 ~g) were labelled with 0.5 mCi 125I (Amersham 
Corp., Arlington Heights IL) under the conditions 
in [13]. 
2.4. Binding assay 
Dilutions of unlabelled Fab fragments were pre- 
pared in PBS containing 5% new born calf serum. 
Aliquots (50/~1) of each dilution were mixed with 
200 ng LDL (5 ~tl) and 15 ng 125I-Fab 
(150 000 cpm) in 5t~l. The mixtures were incu- 
bated at room temperature for 4 h and at 4°C 
overnight. Aliquots (10/~1) of the samples were ap- 
plied to a 1% (w/v) gel of isoelectrofocusing 
quality agarose (Pharmacia Inc.) containing 2.5% 
(w/v) of sorbitol and 5% (v/v) of ampholytes 
pH 3.5-10 (LKB, Bromma) and allowed to mi- 
grate for 50 min in a flat bed electrophoresis appa- 
ratus (LKB Multiphor 2117, LKB Produktor) at a 
constant 7W. The gels were fixed in 5% sulphosa- 
licylic acid/10% trichloroacetic acid, equilibrated 
with 35% ethanol/10% acetic acid, dried and 
stained with Coomassie blue G-250 (Pierce Chemi- 
cal Co., Rockford IL). The bands composed of Fab 
and LDL or LDL-Fab  complexes were identified, 
cut out and the radioactivity counted. Non-specific 
binding of 125I-Fab was determined in the pre- 
sence of 20/~g cold Fab. 
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Fig.1. Separation of bound and free Fab fragments by isoelectrofocusing in agarose. Fig. IA shows the gel stained with 
Coomassie blue and 1B an autoradiogram of the same gel: (1) 1/~g LDL; (2) 5 ~g 3A8 Fab + 15 ng 125I-3A8 Fab; (3) 
15 ng 125I-3A8 Fab + 1 ~tg LDL; (4) 10 ~g 3A8 Fab + 15 ng 1251-3A8 Fab + 1/zg LDL; (5) 10 #g normal mouse Fab + 
15 ng 125I-3A8 Fab + 1 ~tg LDL. The 5% foetal bovine serum normally present in the diluent was omitted to facilitate 
visualization of the bands. 
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2.5. Protein determination 
Protein was measured according to [14] using 
bovine serum albumin as a standard. 
3. RESULTS 
The Fab fragments of 3 monoclonal anti-apo B 
antibodies 5Ell (IgG1), 3A8 (IgG2a) and 4G3 
(IgG2a) have been used in titration studies. An ex- 
ample of the separation of free Fab fragments 
(3A8) from LDL-Fab complexes by isoelectro- 
focusing in agarose is shown in fig.l. The stained 
gel (fig.lA) demonstrates that an excellent separa- 
tion between LDL (lane 1) and Fab (lane 2) is ob- 
tained. An autoradiogram of the same gel (fig.lB) 
shows that when 125I-Fab (3A8) is preincubated 
with excess LDL, LDL-Fab complexes have a pI 
similar to that of LDL and that almost all of the 
radioactivity is localized in this region (lane 3). 
The bound 125I-Fab is displaced by excess un- 
labelled Fab fragments of 3A8 (lane 4) but not by 
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Fig.2. Fab fragments (4 ng to 2 t~g) of 3A8, 4G3 and 
5Eli were incubated with 15 ng of the corresponding 
1251-Fab fragments and 200 ng LDL. Radioactivity asso- 
ciated with bound (B) and free (F) Fab was determined 
after isoetectrofocusing a d the results expressed as 
Scatchard plots. 
Fab fragments of normal mouse IgG (lane 5). Sim- 
ilar results were obtained with Fab fragments of 
5El 1 and 4G3. 
With fresh LDL preparations, - 90% of applied 
radioactivity was recovered, with virtually all asso- 
ciated with either the Fab or LDL bands. In older 
LDL preparations (> 14 days), a distinct band of 
radioactivity was observed between the bands of 
Fab and LDL and which was not associated with 
the point of application. The radioactivity of this 
band (as high as 20% total recovered radioactivity) 
could be displaced with unlabelled anti-apo B Fab 
and may thus represent degradation products of 
LDL. The phenomenon was not prevented by in- 
clusion of the protease inhibitor PMSF. Degrada- 
tion of apo B in the presence of protease inhibitors 
has been described in [15]. 
Varying dilutions of unlabelled Fab fragments 
of 3A8, 4G3 and 5El I containing 15 ng of the cor- 
responding t25I-Fab fragment were incubated with 
a fixed quantity (200 rig) of LDL as in section 2. 
The radioactivity representing free Fab and Fab 
complexed with LDL was determined, and the 
concentration of specifically bound Fab calcu- 
lated. Results of typical experiments for the 3 anti- 
bodies are illustrated in fig.2 in the form of 
Scatchard plots [ 16]. As expected, each of the anti- 
bodies gave a linear binding plot. The maximum 
amount of Fab which could be bound by 200 ng 
LDL, determined from the intercept on the ab- 
cissa, was for 3A8, 14.6 ± 2.0 ng; for 4G3, 14.6 ± 
2.8ng; and for 5El1, 18.7 ± 3.1rig (mean and 
standard eviation, n = 3). The maximum amount 
of Fab fragments of the antibody 3A8 which could 
be bound by 200 ng LDL prepared from 3 dif- 
ferent individuals was also determined. The 3 
preparations of LDL (200 ng), respectively bound 
14.1 ± 2 ng, 15.0 ± 1.4 ng, and 14.7 _+_ 2.0 ng of 
Fab proteins (n = 3). 
4. DISCUSSION 
A maximum of 16 ng Fab (mean value for the 3 
antibodies) was bound by 200 ng LDL protein. 
Knowing a Fab fragment to be 5 × l04 Mr and 
the LDL protein concentration, it can be calcu- 
lated that 1 molecule of Fab reacts with 6 × l05 
Mr of LDL protein. Since, estimates of 5.1 x l05 
[17] and 6.3 x l05 [18] Mr of apo B protein per 
LDL particle have been reported, it follows that a 
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single Fab fragment reacts with 1 LDL particle. 
One arrives at a similar conclusion if the calcula- 
tion is based on the cholesterol content of the LDL 
preparations and a value of 1926 tool cholesterol/ 
tool LDL [18]. 
In these studies, it must be considered that cer- 
tain antigenic determinants of apo B may be hid- 
den in LDL as they are in very low density 
lipoproteins [19]. However, experiments with LDL 
treated by bacterial lipase as in [20] have not sig- 
nificantly increased the immunoreactivity of LDL 
(not shown). Moreover, one cannot ignore the pos- 
sible steric hindrance exerted by one bound Fab 
fragment upon the binding of another to the same 
LDL particle. This would, however, require that 
identical antigenic determinants be situated very 
close together in LDL as shown in [9] that 2 dif- 
ferent monoclonal antibodies (including 5El 1 and 
4G3) can bind simultaneously to the same LDL 
particle. Several criteria, such as cross-reactivity 
with chemically modified LDL, co-titration experi- 
ments and specificity for the LDL receptor ecog- 
nition site, indicate that each of the 3 antibodies 
has a different intramolecular specificity [9] and 
that the 3 determinants tudied are, therefore, 
probably representative of the entire apo B mole- 
cule. 
In agreement with M r 5.5 x 105 for apo B as 
measured by sodium dodecyl sulfate electropho- 
resis [6], our results suggest a single molecule of 
apo B, of -6  x 105 Mr, per LDL particle. How- 
ever, in guanidine hydrochloride, apo B appears to 
form a random coil with M r 2.5 × 105 and has 
been proposed to occur as a dimer in LDL [4,21]. 
Such a model cannot be ruled out on the basis of 
the present experiments since we cannot exclude 
the possibility that only one of the 2 putative 
monomers of apo B may be available for reaction 
with the antibodies. On the other hand, our results 
argue strongly against a model of LDL in which 
apo B is constituted of multiple small subunits 
[22-241. 
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